Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Sarcoma 2Gastrointestinal 2Dermatologic 2CNS 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Solid Tumors 1Solid Tumor 1Advanced Solid Tumors 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × pexidartinib × Other solid neoplasm × Clear all
NCT02734433 2022-04-25

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Daiichi Sankyo

Phase 1 Completed
12 enrolled 22 charts
Other solid neoplasm

Advanced Solid Tumors

NCT01004861 2022-01-04

Safety Study of PLX108-01 in Patients With Solid Tumors

Daiichi Sankyo

Phase 1 Completed
132 enrolled 28 charts
Other solid neoplasm

Solid Tumor

NCT01525602 2020-07-16

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Daiichi Sankyo

Phase 1 Completed
74 enrolled 22 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡